POST-TEST

Exploring Current Considerations and Promising Investigational Approaches for Patients with Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following outcomes was observed in the Phase III MEDALIST trial comparing luspatercept to placebo for patients with lower-risk myelodysplastic syndromes (MDS)?**
   a. The rates of transfusion independence for ≥8 weeks and for ≥12 weeks during weeks 1 to 24 of treatment were both higher with luspatercept
   b. The rate of transfusion independence for ≥8 weeks during weeks 1 to 24 of treatment was higher with luspatercept but not the rate of transfusion independence for ≥12 weeks
   c. No difference was observed between the study arms in the rate of transfusion independence for ≥8 weeks during weeks 1 to 24 of treatment

2. **Which drug description best reflects the mechanism of action of magrolimab?**
   a. Macrophage checkpoint inhibitor and first-in-class monoclonal antibody targeting CD47
   b. Monoclonal antibody targeting heat shock protein 90
   c. Recombinant humanized anti-CD33 monoclonal antibody

3. **In the Phase Ib 5F9005 study, which of the following outcomes was observed with the combination of magrolimab and azacitidine among patients with higher-risk MDS?**
   a. High overall response rates in the overall patient population but not for patients with MDS and a TP53 mutation
   b. High overall response rates for only those patients with MDS and a TP53 mutation
   c. High overall response rates for patients with MDS with and without TP53 mutations

4. **The STIMULUS clinical program includes trials evaluating which novel anti-TIM3 antibody as part of different combination therapies for MDS?**
   a. Sabatolimab
   b. Magrolimab
   c. CC-486

5. **Which of the following Grade 3 or higher adverse events was most frequently reported in the Phase III ASCERTAIN study evaluating the oral combination of decitabine and cedazuridine for patients with low-risk MDS?**
   a. Anemia
   b. Diarrhea
   c. Fatigue
   d. Leukopenia
   e. Neutropenia